Mahdad Noursadeghi
LightNews LightNews
mnoursad.bsky.social
Mahdad Noursadeghi
@mnoursad.bsky.social
280 followers 140 following 33 posts
Posts Replies Media Videos
Reposted by Mahdad Noursadeghi
tomscriba.bsky.social
We are inviting applications for postdoctoral fellows in immunology of TB at the South African Tuberculosis Vaccine Initiative, University of Cape Town. For more information see the attached ad:

idm.uct.ac.za/media/739223
October 9, 2025 at 11:28 AM
Reposted by Mahdad Noursadeghi
yefis-immunology.bsky.social
👶✈️ Balancing caregiving and academic travel?

Join Dr. Laura Pallett for "The Dual Demands of Academic Travel and Caregiving"

🗓️ Sept 25 | 🕒15:00 CEST
🔗https://tinyurl.com/yefis2025-ia2

Hosted by the Improving Academia group of yEFIS
August 25, 2025 at 3:11 PM
Reposted by Mahdad Noursadeghi
gpollara.bsky.social
In @elife.bsky.social: Type I interferon responses contribute to immune protection against mycobacterial infection doi.org/10.7554/eLif...
#TBSky #IDSky #Immunosky
work led by Gillian Tomlinson with support from @mnoursad.bsky.social & @innate2adaptive.bsky.social group (1/5)
Type I interferon responses contribute to immune protection against mycobacterial infection
doi.org
May 31, 2025 at 12:22 PM
Reposted by Mahdad Noursadeghi
thomashasamuels.bsky.social
Very excited to share our new piece of work in the Lancet Global Health @lancetgh.bsky.social – Periskope-CM, a set of personalised risk prediction tools for HIV-associated cryptococcal meningitis mortality: www.thelancet.com/journals/lan...
#IDsky #HIV #GlobalHealth #meningitis #fungal
1/8
Lancet
www.thelancet.com
April 30, 2025 at 7:59 PM
Reposted by Mahdad Noursadeghi
gpollara.bsky.social
Come on down, anyone eligible for a post-doc do consider applying for this exciting project with @jennyrohn.bsky.social, @scottishwormboy.bsky.social & me!

Got a touch of #UTISky #IDSky #ImmunoSky & 🧪 about it! 😉
April 30, 2025 at 9:39 PM
mnoursad.bsky.social
Interested in T cell immunity in TB? Check out our new pre-print on antigen-agnostic identification of generalisable human in vivo Mtb-reactive T cell responses: www.biorxiv.org/content/10.1...
with @qimmuno.bsky.social & @innate2adaptive.bsky.social
Evolution of T cell responses in the tuberculin skin test reveals generalisable Mtb-reactive T cell metaclones.
T cells contribute to immune protection and pathogenesis in tuberculosis, but measurements of polyclonal responses have failed to resolve correlates of outcome. We report the first temporal…
www.biorxiv.org
April 21, 2025 at 5:28 PM
Reposted by Mahdad Noursadeghi
Dr Munyaradzi Musvosvi speaks about the Titan Vaccine Research Project which will allow selection of most promising TB vaccine candidates. This work is supported by the South African mRNA Vaccine Consortium & funded by @samrcza.bsky.social @tomscriba.bsky.social www.youtube.com/watch?v=zwPM...
April 15, 2025 at 1:51 PM
Reposted by Mahdad Noursadeghi
Immunopathology of TB: SATVI researchers discuss a groundbreaking study which investigates the role of lymph nodes in the context of mycobacterium tuberculosis infection and disease. The study was funded by a grant from
@wellcomeleap.bsky.social a program of youtu.be/8_gCOAfWUpw
Immunopathology of TB: Studying the role of the lymph nodes in the TB spectrum.
YouTube video by SATVIUCT
youtu.be
April 15, 2025 at 1:44 PM
mnoursad.bsky.social
2 weeks to the deadline for applications to this post.. take a look, get in touch if you want hear more, don't hold back😎
mnoursad.bsky.social Mahdad Noursadeghi @mnoursad.bsky.social · Mar 27
We’re hiring! Looking for a laboratory post-doc fellow to help us disentangle protective and pathogenic T cells in TB, so we can stratify disease-risk after infection, and develop more effective vaccines. Interdisciplinary science in the heart of London. What's not to like? More here: bit.ly/4iIEiwu
April 11, 2025 at 8:18 AM
Reposted by Mahdad Noursadeghi
tcellvaccineucl.bsky.social
It's just under 1 month to World Immunisation Week 2025 (24th - 30th April)! Check the link below to read more about this crucial campaign for global health.

www.who.int/campaigns/wo...

#WorldImmunisationWeek #VaccinesWork #WHO
World Immunization Week 2025
World Immunization Week, celebrated in the last week of April, aims to promote the life-saving power of immunization to protect people of all ages against vaccine-preventable diseases. Vaccines are on...
www.who.int
March 28, 2025 at 4:21 PM
Reposted by Mahdad Noursadeghi
drmichaelmarks.bsky.social
Academic Clinical Lecturer Posts in Infection now out: for people training in ID in UK & hold/imminently completing PhD.

2 posts @lshtm.bsky.social
shorturl.at/EIUIz

1 at St Georges & 1 at Kings
shorturl.at/8kDY3

If interested in @lshtm.bsky.social posts get in touch.
UK ID people please share!!
A logo showing a person and the words Be Part of Research
March 28, 2025 at 2:54 PM
mnoursad.bsky.social
We’re hiring! Looking for a laboratory post-doc fellow to help us disentangle protective and pathogenic T cells in TB, so we can stratify disease-risk after infection, and develop more effective vaccines. Interdisciplinary science in the heart of London. What's not to like? More here: bit.ly/4iIEiwu
March 27, 2025 at 10:58 PM
mnoursad.bsky.social
This is a great initiative!
February 21, 2025 at 4:47 PM
mnoursad.bsky.social
State of the art in the enigmatic and complex world of immunological determinants of TB👇
December 14, 2024 at 8:28 AM
Reposted by Mahdad Noursadeghi
mayerbarber.bsky.social
Best #Nikolaus 🎅! Our paper on how the 🫁 microenvironment can shape #innate immunity against #viruses is out @sciimmunology.bsky.social This was a herculean effort brilliantly led by @pauljbaker.bsky.social who singlehandedly established the model in the lab during the pandemic. 🧪 #Immunosky 1/9
Graphical summary of our paper. In mice, prior lower airway exposure to diverse inflammatory stimuli, including chronic bacterial infections such as M. tuberculosis, acute bacterial infections such as pulmonary S. aureus, viral infections such as Influenza A, type-II allergic responses such as the OVA-Alum model, activation of pulmonary TLR9 by CpG or pulmonary TLR1/2 by Pam3CSK4 leads to reduced viral burden upon subsequent infection with SARS-CoV-2 (SCV2). (2) This SCV2 restriction occurs prior to induction of SCV2-specific adaptive immune responses and is mediated through innate immune responses, including the induction of IFN-I, TNFα and IL-1 and sustained changes to the TRM (Tissue resident macrophage) cellular compartment and the pulmonary epithelium. (3) Innate cytokine and TLR signaling to both recruited immune cells and the pulmonary epithelium creates a microenvironment in the lung that limits early replication of SCV2. IFN-I signaling to pulmonary ECs (epithelial cells) increases expression of interferon-stimulated genes, that likely cell-intrinsically limit viral replication. TNF- or IL-1 suppress SCV2 independently of IFN-I signaling. TNF acts exclusively through radio-resistant cell types such as the lung epithelium, whereas IL-1 affords control both direct and indirectly, through either stromal and hematopoietic cell types, to restrict overall early SCV2 burden.
December 6, 2024 at 10:38 PM
Reposted by Mahdad Noursadeghi
gpollara.bsky.social
Cool illustration how informative human challenge models can be!

Here #SARSCoV2 challenge model has identified:
👉 insights into differential regulation of IFN-stimulated genes
👉 potential diagnostic biomarkers for early (MX1) & late (IFI27) viral infections

#IDSky #ImmunoSky #COVID19 #MedSky 🧪
December 1, 2024 at 1:26 PM
mnoursad.bsky.social
Also out now.. after peer review, our analysis of blood transcriptional biomarkers of acute respiratory viral infection leveraging the SARS-CoV-2 human challenge model: www.nature.com/articles/s41...
SARS-CoV-2 human challenge reveals biomarkers that discriminate early and late phases of respiratory viral infections - Nature Communications
It’s not always clear whether blood biomarkers are differentially expressed in the time course of viral infections. In this SARS-CoV-2 human challenge study, the authors identify distinct single-gene ...
www.nature.com
November 30, 2024 at 2:50 PM
mnoursad.bsky.social
Reposting for anyone who hasn't clocked this paper yet- fab analysis by @gushamilton.bsky.social @gpollara.bsky.social and team - persuaded anti-IL6 unlikely to increase TB risk , and now need to test it's potential as therapeutic to reduce immunopath. What else can we infer about TB immunology?
November 30, 2024 at 2:28 PM
mnoursad.bsky.social
exciting.. congratulations @gpollara.bsky.social @jennyrohn.bsky.social - look forward to hearing more about it
gpollara.bsky.social Gabriele Pollara @gpollara.bsky.social · Nov 26
This has been a great project to devise and put together, integrating cutting-edge lab models, bioinformatic analyses and clinical samples.

It's now going to be even more fun working with @jennyrohn.bsky.social and @scottishwormboy.bsky.social over the next few years on it! 🎊
#UTISky
jennyrohn.bsky.social Prof Jenny Rohn @jennyrohn.bsky.social · Nov 26
Absolutely thrilled to announce our newly awarded MRC @ukri.org project grant! 🍾 Together with @gpollara.bsky.social & @scottishwormboy.bsky.social, we'll seek novel bacterial virulence and host defence determinants using clinical #UTI samples in my lab's human urothelial microtissue model! #UTISky
November 26, 2024 at 9:58 PM